title: Neonatal B-cell suppression after in utero exposure to R-CHOP.
authors.forename: Ronald Joseph
authors.initials: RJ
authors.lastname: Mittel
authors.forename: Mary Catherine
authors.initials: MC
authors.lastname: Tobin
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Kulik
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects; D015703:Antigens, CD / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001402:B-Lymphocytes / Q000276:immunology*; D001772:Blood Cell Count; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000097:blood / Q000139:chemically induced* / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D011241:Prednisone / Q000009:adverse effects; D011247:Pregnancy / Q000276:immunology; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000970:Antineoplastic Agents; D007136:Immunoglobulins; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone